` HALO (Halozyme Therapeutics Inc) vs CANF (Can Fite Biopharma Ltd) Comparison - Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
Sign Up
Log in

HALO
vs
C
CANF

Over the past 12 months, HALO has significantly outperformed CANF, delivering a return of +21% compared to the CANF's 91% drop.

Valuation Growth Profitability Solvency Stocks Performance
Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
HALO
CANF
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
HALO CANF
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

HALO Intrinsic Value
95.42 USD
Undervaluation 27%
Intrinsic Value
Price $69.29
C
CANF Intrinsic Value
Not Available
Company Last Price Intrinsic Value DCF Value Multiples-Based Value Wall St Target
Halozyme Therapeutics Inc
NASDAQ:HALO
69.29 USD
C
Can Fite Biopharma Ltd
TASE:CANF
465 ILS
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
HALO, CANF

HALO
CANF
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Halozyme Therapeutics Inc
Revenue
C
Can Fite Biopharma Ltd
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
HALO, CANF

HALO
CANF
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Halozyme Therapeutics Inc
NASDAQ:HALO
C
Can Fite Biopharma Ltd
TASE:CANF
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

HALO
83.6%
CANF
0%

Operating Margin

HALO
58.4%
CANF
-2 456.8%

Net Margin

HALO
22.7%
CANF
-2 426.7%

FCF Margin

HALO
25.5%
CANF
-2 210.1%

ROE

HALO
153.6%
CANF
-178.2%

ROA

HALO
13.8%
CANF
-105.5%

ROIC

HALO
29%
CANF
-306.3%

ROCE

HALO
38.2%
CANF
-143.7%

Solvency Comparison

Halozyme Therapeutics Inc
Equity Waterfall
Assets
Liabilities
Equity
What is Equity Waterfall?
C
Can Fite Biopharma Ltd
Equity Waterfall
Assets
Liabilities
Equity
What is Equity Waterfall?
No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
HALO, CANF

Loading
HALO
CANF
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
HALO, CANF

Loading
HALO
CANF
Difference
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y

Performance By Year
HALO, CANF

Loading
HALO
CANF
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare HALO to other stocks
PNEXF
Pharnext SCA
More expensive
vs HALO
ABBV
Abbvie Inc
More expensive
vs HALO
AMGN
Amgen Inc
More expensive
vs HALO
GILD
Gilead Sciences Inc
More expensive
vs HALO
Unlock Full Access to Alpha Spread
Create Free Account
ALPHA SPREAD
Follow us
Join more than 331,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett